Naltrexone ER/bupropion ER in obesity management: a guide to its use

    loading  Checking for direct PDF access through Ovid

Abstract

Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave®, Mysimba™) is an effective adjunct to reduced-calorie diet and increased physical activity for chronic bodyweight management in adults who are either obese, or overweight with at least one bodyweight-related co-morbidity. It provides combination treatment with an opioid antagonist (naltrexone) and a weak dopamine and norepinephrine reuptake inhibitor (bupropion), which synergistically interact in the CNS to control appetite and food intake. In clinical trials in obese adults or overweight adults with controlled hypertension and/or dyslipidaemia (± type 2 diabetes), naltrexone ER/bupropion ER improved bodyweight-related outcomes to a significantly greater extent than placebo, and was generally well tolerated.

Related Topics

    loading  Loading Related Articles